peptide analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The Thiambutenes are a family of opioid analgesic drugs developed at the British research laboratory of Burroughs-Wellcome in the late 1940s. The parent compound thiambutene has no analgesic effects, but several compounds from this group are analgesics with around the same potency as morphine. Notable compounds include dimethylthiambutene, diethylthiambutene, ethylmethylthiambutene, pyrrolidinylthiambutene and piperidylthiambutene. Of these, ethylmethylthiambutene is the most potent, with 1.3x the potency of morphine, pyrrolidinylthiambutene is the least potent at 0.7x, and the rest are all around the same potency as morphine. Diethylthiambutene has been the most widely used, mainly in veterinary medicine. All of these compounds produced anticholinergic and antihistamine side effects, except for two of the weaker compounds diallylthiambutene and morpholinylthiambutene. They also all have a chiral centre on the alpha carbon (where the R1 group is attached) and so have two stereoisomers, with the dextro isomer being the more potent in all cases, although both isomers are active. Three of these compounds are explicitly listed as illegal drugs under UN convention, diethylthiambutene, dimethylthiambutene and ethylmethylthiambutene, and so are illegal throughout the world, but the rest will only be illegal in countries such as the US, Australia and New Zealand that have laws equivalent to the Federal Analog Act.
3-M syndrome or 3M3 is a rare hereditary disorder characterized by severe growth retardation, facial dysmorphia, and skeletal abnormalities. The name 3-M is derived from the initials of the three researchers who first identified it: Miller, McKusick, and Malvaux; they reported their findings in the medical literature in 1972. Mutations in any one of the following three genes: CUL7, OBSL1, and CCDC8 are responsible for the occurrence of this disorder. It is inherited through an autosomal recessive pattern and considered very rare, so far less than 100 cases worldwide have been identified. Diagnosis is based on the presence of clinical features. Genetic testing can confirm the diagnosis and identify the specific gene involved. Treatment is aimed at addressing the growth and skeletal problems and may include surgical bone lengthening, adaptive aids, and physical therapy. An endocrinologist may assist with growth hormone replacement and appropriate evaluations during puberty.
It is the heaviest doubly magic nuclide known. The four primordial isotopes of lead are all observationally stable, meaning that they are predicted to undergo radioactive decay but no decay has been observed yet. These four isotopes are predicted to undergo alpha decay and become isotopes of mercury which are themselves radioactive or observationally stable. There are trace quantities existing of the radioactive isotopes 209–214. The largest and most important is lead-210 as it has by far the longest half-life (22.2 years) and occurs in the abundant uranium decay series. Lead-211, -212, and -214 are present in the decay chains of uranium-235, thorium-232, and uranium-238, further, making these three lead isotopes also detectable in natural sources. The more minute traces of lead-209 arise from three rare decay branches: the beta-delayed-neutron decay of thallium-210 (in the uranium series), the last step of the neptunium series, traces of which are produced by neutron capture in uranium ores, and the very rare cluster decay of radium-223 (yielding also carbon-14). Lead-213 also occurs in a minor branch of the neptunium series. Lead-210 is particularly useful for helping to identify the ages of samples by measuring its ratio to lead-206 (both isotopes are present in a single decay chain). In total, 43 lead isotopes have been synthesized, from 178Pb to 220Pb.
== As a performance-enhancing drug == The possibility of using insulin in an attempt to improve athletic performance was suggested as early as the 1998 Winter Olympics in Nagano, Japan, as reported by Peter Sönksen in the July 2001 issue of Journal of Endocrinology. The question of whether non-diabetic athletes could legally use insulin was raised by a Russian medical officer. Whether insulin would actually improve athletic performance is unclear, but concerns about its use led the International Olympic Committee to ban use of the hormone by non-diabetic athletes in 1998. The book Game of Shadows (2001), by reporters Mark Fainaru-Wada and Lance Williams, included allegations that baseball player Barry Bonds used insulin (as well as other drugs) in the apparent belief that it would increase the effectiveness of the growth hormone he was alleged to be taking. Bonds eventually testified in front of a federal grand jury as part of a government investigation of BALCO. Bodybuilders in particular are claimed to be using exogenous insulin and other drugs in the belief that they will increase muscle mass. Bodybuilders have been described as injecting up to 10 IU of regular synthetic insulin before eating sugary meals. A 2008 report suggested that insulin is sometimes used in combination with anabolic steroids and growth hormone (GH), and that "Athletes are exposing themselves to potential harm by self‐administering large doses of GH, IGF‐I and insulin". Insulin abuse has been mentioned as a possible factor in the deaths of bodybuilders Ghent Wakefield and Rich Piana.
== Georgian military interviews == According to Georgian military interviewed by EurasiaNet, they believed their action initially intended to restore security for Georgian villages in South Ossetia, with one lieutenant from 4th Brigade saying: "Our goal was to put an end to fighting in the area and take control. Nobody in the army expected a war with Russia." Georgian soldiers said they had earlier anticipated an attack from Abkhazia, with the 4th Brigade lieutenant saying that they "were preparing for something in May when Georgia was denied NATO membership [a Membership Action Plan]." There "were no preparations made" for a military action in South Ossetia in August, since "Many were on vacation and we were preparing to go Iraq in the fall." The 4th brigade loaded tanks and missile launchers on a train, destined for the city of Gori, after receiving an unexpected alarm call on 7 August 2008. The 4th Brigade began an operation against South Ossetian separatists during the night of 7–8 August, which marked their first combat, and undertook action in three directions, one of which was intended to deflect South Ossetians from the main Georgian goal. One anonymous mid-ranking commander said Georgian army attempted to take control over an important road to the north of Tskhinvali (leading to the Roki Tunnel), which was being defended by South Ossetian garrison near the village of Tbeti and the first Russian tanks arrived during this battle. The anonymous Georgian commander also said, "We destroyed one tank after another, but they kept coming."
Sources: en.wikipedia.org
=== Hair loss === Studies have reported that PRP is beneficial for alopecia areata and androgenetic alopecia and can be used as an alternative to minoxidil or finasteride. A review reported it to improve hair density and thickness in both genders. A minimum of 3 treatments, once a month for 3 months are recommended, and afterwards a 3-6 month period of continual appointments for maintenance. Factors that determine efficacy include number of sessions, double versus single centrifugation, age, gender, and the injection site.
== Tissue development == Haptotaxis plays a role in organizing cells to form tissues and specific regions of those tissues. Fibronectin and laminin both play a role in adrenocyte mutation into distinctive distribution in the adrenal gland. The adrenocytes migrate centripetally as they mature towards the medulla of the adrenal gland, and this movement may be a result of haptotactic forces mediated by fibronectin and laminin. In nerve cells, axonal growth is mediated by nerve growth factor in a haptotactic manner, where the axon of nerve cells grows along the gradient. This information could be used to possibly develop methods to promote nerve regeneration in patients that have nerve damage. Another regenerative strategy is the use of mesenchymal stem cells, which can differentiate into different kinds of connective tissue in the wound healing process. The haptotaxis is mediated by fibronectin, vitronectin, and type I collagen. A recent study has tentatively proposed the idea that the structures on cells responsible for sensing the membrane protein gradients are attenuated filopodia. Also, the more amount of filopodia present on the leading edge of the migrating cell, the more responsive the cell is to the haptotactic gradient. This is important because there is the possibility that all motile cells that display filopodia may be responding to haptotactic gradients. Further research is required in the subject, but it is clear that more and more kinds of cell undergo haptotaxis than originally believed.
In 594 BCE, beekeeping around Athens was so widespread that Solon passed a law about it: "He who sets up hives of bees must put them 300 feet [90 metres] away from those already installed by another". Greek archaeological excavations of pottery located ancient hives. According to Columella, Greek beekeepers of the Hellenistic period did not hesitate to move their hives over rather long distances to maximize production, taking advantage of the different vegetative cycles in different regions. The spiritual and supposed therapeutic use of honey in ancient India was documented in both the Vedas and the Ayurveda texts.
=== Euphemisms === A huge variety of euphemisms and dysphemisms have been invented to describe semen (for a list of terms see: Sexual slang). Slang terms for semen include cum, jism (also shortened to jizz), spunk (primarily British English), spooge, splooge, load, nut, seed, and love juice. The term cum can also refer to an orgasm (when used as a verb rather than as a noun). The term nut originally referred to a testicle, but can be used to refer to both semen and ejaculation.
Acoustic metamaterials, sometimes referred to as sonic or phononic crystals, are architected materials designed to manipulate sound waves or phonons in gases, liquids, and solids. By tailoring effective parameters such as bulk modulus (β), density (ρ), and in some cases chirality, they can be engineered to transmit, trap, or attenuate waves at selected frequencies, functioning as acoustic resonators when local resonances dominate. Within the broader field of mechanical metamaterials, acoustic metamaterials represent the dynamic branch where wave control is the primary goal. Acoustic metamaterials control, direct and manipulate sound in the form of sonic, infrasonic or ultrasonic waves in gases, liquids and solids. As with electromagnetic waves, sonic waves can exhibit negative refraction. Control of sound waves is mostly accomplished through the bulk modulus β, mass density ρ and chirality. The bulk modulus and density are analogs of permittivity and permeability in electromagnetic metamaterials. Related to this is the mechanics of sound wave propagation in a lattice structure. Also materials have mass and intrinsic degrees of stiffness. Together, these form a resonant system and the mechanical (sonic) resonance may be excited by appropriate sonic frequencies (for example audible pulses). Willis materials exhibit additional nonlocal material parameters for elastic-wave manipulation—analogous to the bianisotropic moduli in electromagnetic media—that couple stress with particle velocity and linear momentum with strain, known as Willis couplings. They are named after J. R.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.